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EXPERT REVIEWCardiac transplant or rotary blood pump: Contemporary evidenceStephen Westaby, MS, PhD, FRCS, FECTS, FESC, FACCCongestive heart failure affects 23 million people world-
wide including 7.5 million in North America (670,000
new cases per year) and 7 million in Europe.1 Inasmuch
as systolic left ventricular dysfunction develops in 10%
of the population over 65 years, the number of patients
with heart failure will double during the next 2 decades.
At any time, 10% of patients are categorized as having
stage D disease—advanced structural heart disease and
symptoms at rest, despite detailed medical and cardiac re-
synchronization therapy. Twenty percent are younger than
65 years of age, comprising between 100,000 to 150,000 pa-
tients for both the United States and Europe.2
The population with chronic preterminal heart failure
has short wretched lives. In the Randomized Evaluation
of Mechanical Assistance for the Treatment of Conges-
tive Heart Failure (REMATCH) study, only 8% of the
medically treated patients were alive at 2 years and re-
mained housebound with severe breathlessness and fa-
tigue in the interim.3 A recurrent sentiment is that they
would sacrifice some duration of survival for periods of
symptomatic relief.4 With the cardiologist as gatekeeper,
cardiac resynchronization therapy is widely used at sub-
stantial cost but cannot be regarded as effective in se-
verely debilitated patients (Figure 1). A meta-analysis
of 14 trials that randomized resynchronization against
medical treatment showed only 59% of the patients in
New York Heart Association (NYHA) class IV supported
with a device to have borderline symptomatic improve-
ment to NHYA class III with no survival benefit.5 Boyle
and associates6 compared functional outcomes for pa-
tients in NYHA class IV after resynchronization or im-
plantation of a pulsatile left ventricular assist device
(LVAD). By 6 months, resynchronized patients achieved
only an additional 6 m in the 6-minute walk test and re-
mained in NHYA class III/IV. In contrast, patients with
an LVAD improved by 341 m, achieving NYHA class I
or II. Notably, the study could not be randomized because
90% of LVAD candidates were bedbound on intravenous
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24 The Journal of Thoracic and Cardiovascular Surgepotential options for those who exhaust maximum medi-
cal therapy are palliative care, a lifetime LVAD, or car-
diac transplantation. Even in affluent health care
systems the vast majority receive only palliative care ir-
respective of age.7
Cardiac transplantation is repeatedly described as the
gold standard treatment for severe heart failure. In epide-
miologic terms, this is similar to describing a lottery win
as the preferred method to gain wealth. On a more opti-
mistic note, recent data from the Fourth INTERMACs An-
nual Report demonstrate 1- and 2-year rotary LVAD
survivals of 80% and 70% in predominantly non–trans-
plant-eligible patients.8 Particularly favorable survival of
85% at 2 years was recorded for patients up to 70 years
without diabetes, renal impairment, or cardiogenic shock.
This considerable achievement is placed into context by
the much less satisfactory 56% and 33% survivals with
the pulsatile HeartMate XVE device (Thoratec Corpora-
tion, Pleasanton, Calif) only 5 years before.9 With im-
provements in technology, the survival curves for
transplantation and mechanical circulatory support are
converging. Carefully selected and electively implanted
patients can anticipate 5 years of event-free survival as
far as out to 7.5 years.10-12 This situation now calls for
prospective randomized trials of cardiac transplantation
versus mechanical circulatory support in specific patient
groups.13 In the meantime, the aim of this review is to ra-
tionalize the evidence base and indications for these com-
plementary therapies.WHAT DOWE KNOWABOUT CARDIAC
TRANSPLANTATION?
Essentially restricted to patients less than 65 years with-
out significant comorbidity, fewer than 2200 donor hearts
per year are made available in the United States and
around 100 in the United Kingdom. The early experience
at Stanford University Medical Center between January
1968 and August 1976 demonstrated overall 1- and
2-year survivals of 52% and 43%, together with a 90%
return to NYHA class I.14 In this era, 95% of patients se-
lected but not receiving a transplant died within 6 months
of evaluation. Because of these original observations,
transplantation has never been tested against alternative
treatments in a prospective randomized model. During
the past 20 years, substantially improved outcomes have
been achieved with drugs and nontransplant heart failure
surgery.15 This has reduced the comparative survival
benefit gained by transplantation in some categories of
patient.ry c January 2013
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COPERNICUS ¼ Carvedilol Prospective
Randomized Cumulative
Survival (Study Group)
CUBS ¼ Clinical Utility Baseline
Study (Group)
ESSENTIAL ¼ Studies of Oral Enoximone
Therapy in Advanced Heart
Failure (Trial)
INTERMACS ¼ Interagency Registry for
Mechanically Assisted
Circulatory Support
INTrEPID ¼ Investigation of
Nontransplant-Eligible
Patients Who Are Inotrope
Dependent (trial)
LVAD ¼ left ventricular assist device
NYHA ¼ New York Heart Association
REMATCH ¼ Randomized Evaluation of
Mechanical Assistance for
the Treatment of Congestive
Heart Failure
REVIVE-IT ¼ Randomized Evaluation of
VAD Intervention before
Inotropic Therapy (study)
UNOS ¼ United Network for Organ
SharingCurrently the median posttransplant longevity is 12.2
years with a 1-year survival of around 85%.16 However,
there are twice as many patients listed for transplantation
annually as there are donor hearts and approximately 8%
die while waiting. Equally, more than 20% of those receiv-
ing transplants die within 3 years.17 Data from the United
Network for Organ Sharing (UNOS) currently suggest ben-
efit for hospitalized patients on inotropic and intra-aortic
balloon pump or LVAD support (UNOS status I) but ques-
tion the value of transplantation for ambulatory patients
whose condition has yet to deteriorate into critically low
cardiac output (UNOS status II).18 At 89%, the 1-year sur-
vival of status II candidates who have not had surgery is
equivalent to or exceeds the outcome of transplantation.
In 2005, 48% of heart transplant candidates had spent
more than 2 years on the waiting list and survival of status
I patients approached 70%.19 These data echo the findings
of Deng and coworkers,20 who showed that status II
wait-listed patients who did not receive a donor heart hadThe Journal of Thoracic and C3- and 4-year survivals similar to those of patients receiving
a transplant. Around 30% of status II patients improve
symptomatically and prognostically when managed by
a specialist heart failure team. Patients are then considered
too well for transplantation if they demonstrate a sustained
improvement in peak oxygen uptake of more than 2 mL $
kg1 $ min1. Furthermore, Shah and colleagues21 showed
that 1- and 3-year survivals for status II patients removed
from the waiting list were 100% and 92%, respectively. Id-
iopathic dilated cardiomyopathy, the most frequent diagno-
sis in transplant patients, often showed spontaneous
improvement and better prognosis than ischemic cardiomy-
opathy. In addition, some patients with idiopathic dilated
cardiomyopathy respond to mechanical ventricular unload-
ing with reverse remodeling and sustained improvement in
left ventricular function.22
For status I candidates, predictors of early death (within 2
months) are the need for mechanical ventilation, valvular
cardiomyopathy, UNOS status Ia, serum creatinine greater
than 1.5 mg/dL, presence of an intra-aortic balloon pump,
age greater than 60 years, use of intravenous inotropic
drugs, body weight less than 70 kg, and pulmonary capillary
wedge pressure less than 20 mm Hg.23 Without treatment,
these patients have a projected mortality varying from im-
minent to more than 50% at 6 months, whereas transplant
survival exceeds 80% at 1 year and is almost 50% at 10
years. Eligibility for transplantation remains dependent on
age and comorbidity with direct sequelae of chronic heart
failure (pulmonary hypertension and renal impairment)
mitigating against suitability.24
In the absence of randomized trials, recent comprehen-
sive registry data from UNOS help to define who should
and should not receive a transplant. In an analysis of
22,385 patients undergoing transplantation, Kilic and asso-
ciates25 found that 42% survived for 10 years or more, but
for those who did not reach 10 years, mean survival was
3.7  3.3 years. Clear predictors of transplant longevity
were age less than 55 years, white race, younger donor
age, and shorter donor heart ischemic time. Diabetes, renal
impairment, and the need for preoperative ventilation mil-
itated against long-term survival. In a separate report, the
same authors reviewed data from 15,960 patients who
had received transplants (1998-2008), observing the influ-
ence of metabolic risk factors on survival.26 Preoperative
hypertension was found in 40% of patients, obesity in
25%, and diabetes in 21%. Only 40% had none of the
3, whereas 18% had 2 and 4% had all 3 risk factors. Those
with all 3 were older (mean age, 55 vs 50 years), more
likely to be male, and had significantly higher serum creat-
inine levels. They were more likely to have ischemic than
idiopathic dilated cardiomyopathy and to receive an LVAD
(20%) as bridge to transplantation. From multivariate anal-
ysis incorporating 22 covariates, each of the 3 factors was
found to be a significant predictor for reduced survival.ardiovascular Surgery c Volume 145, Number 1 25
FIGURE1. Myocardial regeneration therapy. Plain radiograph of a patient
with ischemic cardiomyopathy with cardiac resynchronization and an im-
plantable defibrillator who was inotrope dependent in the hospital for 3
months. He received a Jarvik FlowMaker device with a skull pedestal
power delivery plus intramyocardial injection of autologous bone marrow
stem cells. Twelve months later he was in New York Heart Association
class I with objective evidence of improved myocardial perfusion and con-
tractility. (From Anastasiadis K, Antonitsis P, Doumas K, Koliakos G, Ar-
giriadou H, Vaitsopolou C, et al. Stem cells transplantation combined with
long-term mechanical circulatory support enhances myocardial viability in
end-stage ischemic cardiomyopathy. Int J Cardiol. 2012;155:e51-3. Re-
printed with permission from Elsevier.)
Expert Review WestabyDiabetes independently increased the odds of mortality by
22%, obesity by 17%, and hypertension by 10% (each P
<.01). When patients with all 3 risk factors were compared
with those with none, the increased mortality risk was
63%. Thus the adverse impact was exponentially greater
when diabetes, obesity, and hypertension were present in
combination. Kilic’s study suggested a higher mortality
risk for those with a body mass index greater than
30 kg/m2.26 In the meantime, a recent UNOS analysis
suggested that a body mass index between 30.0 and
34.9 kg/m2 did not increase mortality but that patients
with a body mass index greater than 35 kg/m2 had worse
survival.27 These data support the findings of Lietz and col-
leagues28 that both cachectic and obese patients are subject
to poor early posttransplant outcomes.26 The Journal of Thoracic and Cardiovascular SurgeIMPROVING TRANSPLANT SELECTION
CRITERIA ON THE BASIS OF CURRENT
EVIDENCE
In the absence of prospective randomized trial data,
the transplant registries in comparison with clinical trials
of medical therapy provide the best comparative evi-
dence base. In the United States, approximately 75%
of heart transplantations are now performed in UNOS
status I patients. Figures 2 and 3 depict the effect of
medical treatment from major trials in patients in
the UNOS waiting list for heart transplantation
stratified as status Ia, Ib, and II. On the basis of these
observations, transplantation may not provide benefit
to patients deemed status Ib or II.29 Patients whose con-
dition can be improved by beta-blockers or resyn-
chronization/defibrillator therapy (COPERNICUS and
COMPANION type of patients) will probably not derive
benefit from transplantation.30,31 Patients in the UNOS
1b category may remain stable and retain benefit
from medical treatment or will progress to refractory
terminal heart failure. Patients with the most advanced
forms (ESSENTIAL and REMATCH) have the greatest
risk of mortality when compared with those who
receive a transplant and are likely to derive benefit.3,32
Accordingly, potential transplant benefit should be
assessed against the predicted outcome after recom-
pensation and implementation of optimal medical
management.
In summary, registry data indicate the best survival ad-
vantage for UNOS status Ia patients younger than 55 years
of white race without metabolic risk factors, who benefit
from a donor heart less than 40 years of age with short is-
chemic time. It could be argued that scarce donor hearts
should be allocated only to patients with projected long-
term survival. Cardiac transplantation remains necessary
for young patients with palliated complex congenital heart
disease or dilated cardiomyopathy with poor right ventric-
ular function. Together, these could account for all avail-
able donor hearts. This raises the question as to whether
older patients with ischemia and metabolic risk factors
should be considered. In practice, this route seems harsh
and morally questionable unless alternative treatment is
available.IS ALIFETIMELVADAREALISTICALTERNATIVE
TO TRANSPLANTATION
The pulsatile LVAD was designed to replicate the fail-
ing left ventricle; thus its size was determined by the
need to produce stroke volume at similar pulse rates to
the native heart. Over the past 10 years, pump technology
has changed markedly with the revelation that pulse pres-
sure is not a fundamental requirement in the human circu-
lation.33 It is also clear that modest increases in blood flowry c January 2013
FIGURE 2. General comparative analysis of outcomes of patients listed for heart transplantation as status 1A, 1B, and 2, patients undergoing orthotopic
heart transplantation, and patients in the placebo groups reported by major clinical trials. OPTN, Organ Procurement and Transplantation Network; UNOS,
United Network for Organ Sharing; ISHLT, International Society for Heart and Lung Transplantation; REMATCH, Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure; ESSENTIAL, Studies of Oral Enoximone Therapy in Advanced Heart Failure (Trial); COPER-
NICUS, Carvedilol Prospective Randomized Cumulative Survival (Study Group); CONSENSUS; MERIT HF; MIRACLE; US Carvedilol; CIBIS; RALES;
VEHEFT; BEST; MADIT; DEFINITE; SOLVD Rx; SCD CHF. (From Cadeiras M, Von Beyern MP, Deng MC. Cardiac transplantation. Any role left?
Heart Fail Clin. 2007;3:321-48. Reprinted with permission from Elsevier.)
Westaby Expert Review(in the range of 3-4 L/min) are effective in relieving symp-
toms and reversing both the humeral and cytokine changes
of heart failure. The new rotary blood pumps are consid-
erably more patient friendly with lower complication
rates. The surgery and postoperative care are less intimi-
dating, and mechanical reliability is already established
for a number of devices.10-12 As such, the rotary LVADs
provide an unrestricted ‘‘off the shelf’’ solution to
relieve symptoms and improve quality of life in those
without access to transplantation.
Lifetime circulatory support has the potential to super-
cede transplantation by a factor of 20:1. A recent Society
of Thoracic Surgeons/Food and Drug Administration Think
Tank (Washington DC, September 2011) predicted the need
for 40,000 LVADs annually in the United States, although at
current costs this could account for half of the national heart
failure budget ($35 billion). Because the devices all cost the
same as a Porsche automobile, ‘‘intention to treat’’ with an
implantable rotary LVAD should be on a long-term basis.
Artificial differentiation between ‘‘bridge to transplant’’FIGURE 3. General comparative analysis of outcomes patients listed for heart t
transplantation, mechanical circulatory support device implantation, and patient
legend to Figure 2. (From Cadeiras M, Von Beyern MP, Deng MC. Cardiac tran
permission from Elsevier.)
The Journal of Thoracic and Cor ‘‘destination therapy’’ groups is no longer useful inas-
much as patients are switched from one strategy to another
depending on clinical progress and evolving patient prefer-
ence.8 Even so-called ‘‘fixed pulmonary vascular resis-
tance’’ (7.5 Wood units) has been shown to be
reversible during LVAD unloading, allowing patients unac-
ceptable for transplantation to receive a donor heart in
time.34
Although acute cardiogenic shock and chronic severe
heart failure cohorts are fundamentally different, they over-
lap when chronic heart failure decompensates precipitously
and the patient needs to be rescued. Lietz and Miller35 dem-
onstrated the futility of long-term VAD deployment in
shock/multiorgan failure patients. They retrospectively al-
located 280 HeartMate XVE patients into low, medium,
high, and very high risk preoperative cohorts that provided
1-year mortalities of 19%, 38%, 72%, and 89%, respec-
tively. In a more recent analysis of patients with rotary
blood pumps from the INTERMACS database, Boyle and
associates36 showed a dramatic difference in 3-year survivalransplantation as status 1A, 1B, and 2, patients undergoing orthotopic heart
s in the treatment groups reported by major clinical trials. For acronyms, see
splantation. Any role left? Heart Fail Clin. 2007;3:321-48. Reprinted with
ardiovascular Surgery c Volume 145, Number 1 27
Expert Review Westabybetween those operated on urgently in cardiogenic shock
(INTERMACS I) versus severely symptomatic but elec-
tively implanted ambulatory patients in INTERMACS
profiles 4 to 7 (51.1% vs 95.8%; P ¼ .011). For inotrope-
dependent patients in profiles 2 and 3, the survival differ-
ence appeared substantial but failed to achieve statistical
significance (68.8% vs 95.8%; P ¼ .065). From an eco-
nomic standpoint, the patients who had elective implanta-
tion left the hospital in 14 days versus 49 days for
survivors of cardiogenic shock (P<.001). These and other
studies emphasize that carefully considered patient selec-
tion has an important impact on outcome and is the key to
cost-effectiveness in a destination therapy program.37-39
Clearly, a less expensive short-term LVAD, extracorporeal
membrane oxygenation, or a total artificial heart should
be used for salvage.40 The implantable rotary LVADs are
best deployed electively, preferably without conventional
cardiopulmonary bypass, and perhaps with cell therapy in
patients with ischemic cardiomyopathy.41,42 A more
considered and selective approach greatly simplifies the
perioperative management, optimizes outcome, and
reduces costs. The LVAD then becomes ‘‘spend to save
technology’’ by preventing numerous hospital admissions
for palliation of heart failure.
Currently, the preferred candidates for lifetime support
are those who are not yet hospitalized on inotropic therapy
but are severely symptomatic and virtually housebound
with poor survival prospects.43 Risk profiling based on
data from the pulsatile LVAD (REMATCH) era does not
translate directly to patients with a rotary blood pump inas-
much as virtually all prospective patients were then on in-
travenous inotropic support.44 A survey of patients with
chronic ambulatory heart failure confirmed that they would
consider an LVAD if they could walk less than 100 yards or
were thought to have less than 12 months’ projected sur-
vival.45 This provided the ‘‘one block or one year rule’’ as
the trigger for referral for circulatory support. The latest
INTERMACs data show a decrease in patients with cardio-
genic shock taken directly for lifetime support but show an
increase in comorbid risk factors associated with greater
age and previous coronary bypass surgery.8
After REMATCH, further prospective randomized trials
of LVAD versus continued medical therapy were deemed
unnecessary for INTERMACS profile 1,2,3 patients.3
They remain justified in the housebound, walking wounded,
and advanced NYHA class III cohorts (INTERMACS 4-7)
and in UNOS status II transplant candidates. Together with
INTrePID and CUBS, REMATCH spelled the end for the
pulsatile LVADs.46,47 These have not been used in the
United States since January 2010.8 In contrast, 3 key ele-
ments account for the improvement in rotary blood pump
outcomes. These are progressive improvements in bioengi-
neering, revisions of patient selection, and refinement of
perioperative management. Slaughter and associates4828 The Journal of Thoracic and Cardiovascular Surgeshowed the jump from pulsatile to continuous flow technol-
ogy to be highly significant. Comparing the HeartMate
XVE with HeartMate II in patients aged 26 to 81 years (me-
dian, 64 years) undergoing destination therapy, actuarial
survival at 2 years was 24% versus 58% (P ¼ .008). There
were significant reductions in major adverse events (infec-
tion, renal failure, right ventricular failure) although the in-
cidence of stroke was similar (17% for HeartMate II, 14%
for HeartMate XVE). The leading cause of death among pa-
tients with HeartMate II was hemorrhagic stroke in 9% ver-
sus 10% for HeartMate XVE. Embolic stroke rate for
HeartMate II (6/100 patient-years) was similar to that expe-
rienced by patients with chronic heart failure and atrial fi-
brillation. Because the percutaneous driveline was smaller
and less stiff, driveline infection rate was 50% of that expe-
rienced with the HeartMate XVE.48
In Europe, the Jarvik 2000 device (Jarvik Heart, Inc, New
York, NY) has been used extensively with power delivery
through a skull-mounted pedestal designed to minimize
driveline infection49 (Figure 1). Based on cochlear implant
hearing technology and with rigid fixation to the skull, there
is no movement in relation to scalp skin. The scalp itself is
highly vascular with little fat. Healing occurs rapidly and in-
fection is rare. The blood pump is remote from the site of
power delivery and all extracorporeal components (cables,
controller, and batteries) exposed to wear and tear are ex-
changeable. The system effectively eliminates the sequence
of pyogenic bacterial driveline infection superceded by fun-
gal colonization after antibiotic treatment.50 Emphasizing
the potential for this approach, the first patient to receive
the system as a permanent solution (2000) survived for
7½ years with good quality of life (more than 10% of his
overall life span).12 There were no device-related complica-
tions and he died of a noncardiac cause. In the current US
Jarvik bridge to transplant trial with new cone bearings in
the pump, 6-, 12-, and 24-month survivals are 91%, 87%,
and 87%, respectively (unpublished data from Jarvik Heart,
New York, NY).
In 2011, Strueber and coworkers10 reported a multicenter
prospective clinical evaluation of the HeartWare Ventricular
Assist System (HeartWare Inc, Framingham, Mass), which
included 50 NYHA class IV transplant candidates. The
mean duration of pump support was 348 days (range,
12-847 days) and there were no mechanical failures. Nine
(18%) patients died during support at a median duration
of 94 days (range, 13-515 days). Survival of the patients
who underwent transplantation, manifest left ventricular
recovery, or were on ongoing support was 90% at 6 months,
85% at 1 year, and 79% at 2 years. All patients recovered
from chronic heart failure with improvements in end-
organ function, quality of life, and neurocognitive function.
Embolic stroke occurred in only 2 of the 50 patients within
the first 30 days. However, 4 pumps were replaced because
of thrombus formation, 2 through bearing problems, andry c January 2013
TABLE 1. Preferred patient characteristics with regard to suitability
for cardiac transplantation or a rotary blood pump
Transplant LVAD
Age (y) <55 <75
NYHA functional class IV III/IV
INTERMACS profile 1-3 3-6
UNOS status I II
Peak VO2 (mL $ kg
1 $ min1) <12 <12
LVEF (%) <25 <25
PVR (Wood units) <2.5 <7.5









TR/AR N/A Needs repair
Intracardiac shunt N/A Needs repair




Treated malignancy Contraindication Acceptable
Advanced vascular disease Contraindication Acceptable
Severe lung disease Heart–lung
transplant
Contraindication
Hematologic/bleeding issues Case by case Contraindication
Previous cardiac surgery Acceptable Acceptable
Psychosis/cognitive dysfunction Case by case Contraindication
Family support Not essential Essential
Proximity to center Not essential Essential
LVAD, Left ventricular assist device; NYHA, New York Heart Association; INTER-
MACS, Interagency Registry for Mechanically Assisted Circulatory Support;
UNOS, United Network for Organ Sharing; Vo2, volume of oxygen use; LVEF, left
ventricular ejection fraction; PVR, pulmonary vascular resistance; BMI, body mass
index; CVP, central venous pressure; TR/AR, tricuspid regurgitation/aortic regurgita-
tion; INR, international normalized ratio; N/A, not applicable. *Acceptable if due to
right heart failure but not established cirrhosis or portal hypertension.
TABLE 2. Ideal candidates from a prognostic and economic
standpoint
 Cardiac transplant: Age<50 years, UNOS status I, INTERMACS
1-2 without metabolic risk factors (obesity, diabetes, hypertension)
or peripheral vascular disease with recoverable renal and hepatic
dysfunction and low pulmonary vascular resistance. Should receive
a young donor heart with short ischemic time.
 Rotary blood pump: Age<70 years, UNOS status II, INTERMACS
3-6 without right heart failure, hepatic dysfunction, metabolic risk
factors, dialysis-dependent renal failure or contraindication to
anticoagulation. Should undergo an elective implant for symptomatic
relief. Needs a supportive family or equivalent.
UNOS, United Network for Organ Sharing; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support.
Westaby Expert Reviewa seventh owing to complications of implantation (14%
overall).
In a single-center study of 55 patients who received the
HeartMate II LVAD between 2005 and 2010, Adamson
and coworkers51 compared outcomes between patients
who were older (n ¼ 30) or younger (n ¼ 25) than 70 years
of age. All patients were in NYHA class IVand not amena-
ble to medical therapy. Kaplan-Meier survival for patients
older than 70 years (75% at 1 year and 70% at 2 years)
was not statistically different from that of younger patients
(72% at 1 year and 65% at 2 years; P ¼ .80). The authors
concluded that whereas younger patients wished to live lon-
ger, the older age group wanted to live better and were very
appreciative of the improved quality of life.
To date, established right heart failure remains a contrain-
dication to destination therapy although a fall in pulmonary
artery pressure may improve the situation.34 Predictive
guidelines are imperfect and total artificial hearts are not
yet appropriate for widespread use in this context.8 Biven-
tricular rotary blood pump support has been used in the
bridge to transplant setting, but there are problems in balanc-
ing pulmonaryversus systemic flow. Fit of the inflowcannula
in the crescentic right ventricle is also problematicwhen pul-
monary artery pressure falls and cavity size decreases.52
THE WAY FORWARD
With expansion of the evidence base, patterns of care are
emerging. Transplantation is the restricted commodity and is
predominantly directed toward young status I patients with
acute or chronic heart failure to prolong life. In contrast,
the implantable rotary pumps are increasingly deployed
electively for refractory symptoms in non–transplant-eligi-
ble patients, those unlikely to receive a donor heart, and
the elderly.38 Patient characteristics define suitability for
each treatment (Table 1). Suggestions regarding the opti-
mum candidate for transplant versus mechanical support
are presented in Table 2. The differences indicate that the 2
approaches are complementary rather than competitive.
We have reached the stage whereby long-term LVAD
therapy should be discussed with transplant candidates
who face a prolonged wait for a donor heart (risking in-
terim death) or be offered a marginal organ. Further refine-
ments of the LVAD approach using adjuvant medical
therapy or direct stem cell injection to improve myocardial
contractility may eventually provide equivalence between
transplant and LVAD.42,53 Why then were only 464
destination therapy LVADs implanted in the United
States in 2010? First, there are perceived difficulties in
identifying patients who are progressing toward an early
death but are not yet dying.54 These are usually UNOS sta-
tus II patients, many of whom would choose LVAD support
for symptomatic relief irrespective of survival benefit.4 To
allow the younger of these patients (<70 years) to deterio-
rate to a cachectic state with multiorgan dysfunctionThe Journal of Thoracic and Cbefore considering an LVAD could now be considered
neglectful.43 Second is many cardiologists’ perception of
contemporary mechanical circulatory support. Based
on publications about first-generation LVADs, this isardiovascular Surgery c Volume 145, Number 1 29
Expert Review Westabycharacterized by device failure and debilitating complica-
tions.3 In the absence of well-powered prospective studies
of long-term rotary blood pump use, it has been difficult to
persuade the cardiologist or regulatory bodies of the bene-
fits of this approach. Stevenson and colleagues54 suggest
that current outcomes already justify extension of LVAD
therapy to INTERMACS profiles 4, 5, and possibly 6.
(Eighty percent of LVADs are currently used for bridge
to transplant in INTERMACS I and 2 patients.) Extrapolat-
ing from this, when mean LVAD survival exceeds 3 years,
destination therapy could be contemplated before
transplantation.
The decision to use an LVAD for symptomatic relief and
potential prognostic benefit in profiles 4 to 6 remains con-
troversial. The surgical risks are less but so is the net benefit.
The current Randomized Evaluation of VAD Intervention
before Inotropic Therapy (REVIVE-IT) study should help
with this. Meanwhile, trials of medical therapy and cardiac
resynchronization generally show survivals of 80% and
75% at 1 and 2 years, respectively.42 Although blood pumps
provide better functional capacity and symptomatic relief,
they should achieve equivalent survival if they are to affect
this population. Significantly, Eckman and associates55
compared consecutive LVAD patients with INTERMACS
4 to 6 profiles with their preimplant predicted Seattle Heart
Failure Model survival. One- and 2-year survivals were
85% and 80%, respectively, providing an absolute 27% re-
duction in predicted mortality by 2 years.
The catch 22 of lifetime LVAD therapy is that long-term
blood pumps are largely limited to transplant centers and
overtly non–transplant-eligible patients who may be candi-
dates are not referred to these hospitals.56 Many patients
who are submitted for palliative care alone could gain
symptomatic relief and several extra years of life with an ap-
propriate blood pump. So far, this message has not reached
the primary care physician. Given the potential demand as
transplantation declines in some countries, lifetime LVAD
therapy could reasonably be performed in tertiary centers
that specialize in nontransplant heart failure surgery.57
This approach is already endorsed in the United States
and regulatory guidelines are established.58 Devices are im-
proving rapidly and can be made available in sufficient
numbers to address heart failure epidemiology.
In end-stage renal failure, the options are a kidney trans-
plant or mechanical blood filtration (dialysis). Few patients
younger than 80 years are just left to die. We now have the
direct analogy in heart failure. In my view, both the mys-
tique and the prohibitive device costs must be removed
from LVAD therapy. Even the terminology should change.59
This may involve movement away from the transplant set-
ting and widespread introduction into conventional heart
failure surgery programs alongside ‘‘myocardial regenera-
tion therapy.’’42,60 Unabated developments in pump safety
and simplicity will justify studies of LVAD versus30 The Journal of Thoracic and Cardiovascular Surgeresynchronization therapy in patients in NYHA class
III/IV. Severe heart failure will then sit firmly in the
surgical domain.References
1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al,
American Heart Association Statistics Committee and Stroke Statistics Subcom-
mittee. Heart disease and stroke statistics—2012 update: a report from the Amer-
ican Heart Association. Circulation. 2012;125:e2-220.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al.
Heart disease and stroke statistics—2010 update. A report from the American
Heart Association. Circulation. 2010;121:948-54.
3. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W,
et al. Long term mechanical left ventricular assistance for end stage heart failure.
N Engl J Med. 2001;345:1435-43.
4. Stewart GC, Brookes K, Pratibhu PP, Tsang SW, Semigran MJ, Smith CM, et al.
Thresholds of physical activity and life expectancy for patients considering des-
tination left ventricular assist devices. J Heart Lung Transplant. 2009;28:863-9.
5. McAlister FA, Ezekowitz J, Hooton N, Vendermeer B, Spooner C, Dryden DM,
et al. Cardiac resynchronization therapy for patients with left ventricular systolic
dysfunction. A systematic review. JAMA. 2007;297:2502-14.
6. Boyle AJ, Russel SD, John R, Chen L, Aaronson KD, Farrar DJ. Comparing im-
provements in functional capacity in NYHAClass IV patients between a contin-
uous flow left ventricular assist device and cardiac resynchronization therapy.
J Am Coll Cardiol. 2008;5(Suppl A):A69.
7. Deng MC, Ardehali A, Shemin R, Hickey A, MacLellan R, Fonarow G. Relative
roles of heart transplantations and long term mechanical circulatory support in
contemporary management of advanced heart failure—a critical appraisal ten
years after REMATCH. Eur J Cardiothorac Surg. 2011;40:781-2.
8. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al.
The fourth INTERMACS Annual Report: 4000 implants and counting. J Heart
Lung Transplant. 2012;31:117-26.
9. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Out-
comes of left ventricular assist device implantation as destination therapy in the
post-REMATCH era: implications for patient selection. Circulation. 2007;116:
497-505.
10. Strueber M, O’Driscoll G, Jansz P, Khagani A, LevyWC,Weiselthaler GM.Mul-
ticenter evaluation of an intrapericardial left ventricular assist system. J Am Coll
Cardiol. 2011;57:1375-82.
11. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Ex-
tended mechanical circulatory support with a continuous flow rotary left ventric-
ular assist device. J Am Coll Cardiol. 2009;54:312-21.
12. Westaby S, Banning A, Neil D, Poole-Wilson P, Frazier OH. Optimism derived
from 7.5 years of continuous flow circulatory support. J Thorac Cardiovasc Surg.
2010;139:e45-7.
13. ShahMR, Starling RC, Longacre LS,MehraMR, National Heart Lung and Blood
Institute Working Group. Heart transplantation research in the next decade. A
goal to achieving evidence based outcomes. J Am Coll Cardiol. 2012;59:1263-9.
14. Hunt SA, Rider AK, Stinson EB, Griepp RD, Schroeder JS, Harrison DC, et al.
Does cardiac transplantation prolong life and improve its quality? An updated re-
port. Circulation. 1976;54(Suppl):III56-60.
15. Westaby S. Non transplant surgery for heart failure. Heart. 2000;83:603-10.
16. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al.
Registry of the International Society for Heart and Lung Transplantation: twenty-
third official adult heart transplantation report—2006. J Heart Lung Transplant.
2006;25:869-79.
17. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation:
twenty-seventh official adult heart transplantation report—2010. J Heart Lung
Transplant. 2010;29:1089-103.
18. Leitz K, Miller LW. Improved survival of patients with end stage heart failure
listed for heart transplantation. J Am Coll Cardiol. 2007;50:1282-90.
19. Hunt SA. Taking heart—cardiac transplantation. N Engl J Med. 2006;355:231-5.
20. Deng MC, DeMeester JMJ, Smits JM, Heinecke J, Scheld HH, on behalf of the
COCPIT study group. The effect of receiving a heart transplant: analysis of a na-
tional cohort entered onto waiting list, stratified by heart failure severity. BMJ.
2000;321:540-5.
21. Shah NR, Rogers JD, Ewald GA, Pasque MK, Geltman EM, Bailey MS, et al.
Survival of patients removed from the heart transplant waiting list. J Thorac
Cardiovasc Surg. 2004;127:1481-5.ry c January 2013
Westaby Expert Review22. Muller J,Wallukat G,WengY, DandelM, Ellinghaus P, Huetter J, et al. Predictive
factors for weaning from a cardiac assist device. An analysis of clinical, gene ex-
pression and protein data. J Heart Lung Transplant. 2001;20:202-7.
23. Kirklin JK, McGiffin DC, Pinderski LJ, Tallaj J. Selection of patients and tech-
niques of heart transplantation. Surg Clin North Am. 2004;84:257-87.
24. Deng MC. Orthotopic heart transplantation: highlights and limitations. Surg Clin
North Am. 2004;84:179-99.
25. Kilic A, Weiss ES, George TJ, Arnaoutakis GJ, Yuh DD, Shah AS, et al. What
predicts long term survival after heart transplantation? An analysis of 9,400
ten year survivors. Ann Thorac Surg. 2012;93:699-704.
26. Kilic A, Conte JV, Shah AS, Yuh DD. Orthotopic heart transplantation in patients
with metabolic risk factors. Ann Thorac Surg. 2012;93:718-24.
27. Russo MJ, Hong KN, Davies RR, Chen JM, Mancini DM, Oz MC, et al. The ef-
fect of body mass index on survival following heart transplantation: do outcomes
support consensus guidelines? Ann Thorac Surg. 2010;251:144-52.
28. Lietz K, John R, Burke EA, Ankersmit JH, McCue JD, Naka Y, et al. Pretrans-
plant cachexia and morbid obesity are predictors of increased mortality after
heart transplantation. Transplantation. 2001;72:277-83.
29. Cadeiras M, Von Beyern MP, Deng MC. Cardiac transplantation. Any role left?
Heart Fail Clin. 2007;3:321-48.
30. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al, Carve-
dilol Prospective Randomized Cumulative Survival Study Group. Effect of car-
vedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:
1651-8.
31. Bristow MR, Saxon LA, Boehmer J, Kruegar S, Kass DA, De Marco T, et al.
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure
(COMPANION) Investigators. Cardiac-resynchronization therapy with or with-
out an implantable defibrillator in advanced chronic heart failure. N Engl J Med.
2004;350:2140-50.
32. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Rahko PS, Dec GW,
et al. Low dose enoximone improves exercise capacity in chronic heart failure.
Enoximone Study Group. J Am Coll Cardiol. 2000;36:501-8.
33. Westaby S, Bertoni G, Cleland C, Nishinaka T, Frazier OH. Circulatory support
with attenuated pulse pressure alters human aortic wall morphology. J Thorac
Cardiovasc Surg. 2007;133:575-6.
34. Mikus E, Stepanenko A, Krabatsch T, Loforte A, Dandel M, Lehmkuhl HB, et al.
Reversibility of fixed pulmonary hypertension in left ventricular assist support
recipients. Eur J Cardiothorac Surg. 2011;40:971-7.
35. Lietz K, Miller LW. Destination therapy: current results and future promise.
Semin Thorac Cardiovasc Surg. 2008;20:225-33.
36. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, et al. Clinical
outcomes for continuous flow left ventricular assist device patients stratified by
pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:
402-7.
37. Wilson SR, Mudge GH, Stewart CG, Givert MM. Evaluation for a ventricular
assist device. Selecting the appropriate candidate. Circulation. 2009;119:
2225-32.
38. Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the selection of pa-
tients for destination therapy left ventricular assist device. Circ Heart Fail. 2012;
5:286-93.
39. Lund LH, Mathews J, Aaronson K. Patient selection for left ventricular assist de-
vices. Eur J Heart Fail. 2010;12:434-43.
40. Westaby S, Anastasiadis K, Wieselthaler GM. Cardiogenic shock in ACS. Part 2:
Role of mechanical circulatory support. Nat Rev Cardiol. 2012;9:195-208.
41. Anastasiadis K, Antonitsis P, Argiriadou H, Khayat A, Papakonstantinou C,
Westaby S, et al. Use of minimal extracorporeal circulation circuit for left ven-
tricular assist device implantation. ASAIO J. 2011;57:547-9.The Journal of Thoracic and C42. Anastasiadis K, Antonitsis P, Doumas K, Koliakos G, Argiriadou H,
Vaitsopolou C, et al. Stem cells transplantation combined with long-term me-
chanical circulatory support enhances myocardial viability in end-stage ischemic
cardiomyopathy. Int J Cardiol. 2012;155:e51-3.
43. Westaby S. Destination therapy. Time for real progress. Nat Clin Pract Cardio-
vasc Med. 2008;5:477-83.
44. Teuteberg JJ, Ewald GA, Adamson RM, Leitz K, Miller LW, Tatooles AJ, et al.
Risk assessment for continuous flow left ventricular assist devices: does the des-
tination therapy risk score work? J Am Coll Cardiol. 2012;60:44-51.
45. Allen LA, Rogers JG,Warnica JW, Disalvo TG, Tasissa G, Binanay C, et al. High
mortality without ESCAPE: the registry of heart failure patients receiving pulmo-
nary artery catheters without randomization. J Card Fail. 2008;14:661-9.
46. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al,
INTrEPID Investigators. Chronic mechanical circulatory support for inotrope de-
pendent heart failure patients who are not transplant candidates: results of the
INTrEPID trial. J Am Coll Cardiol. 2007;50:741-7.
47. Pae WE, Connell JM, Adelowo A, Boehmer JP, Korfer R, El-Banayosy A, et al,
Clinical Utility Baseline Study (CUBS) Group. Does total implantability reduce
infection with the use of a left ventricular assist device? The LionHeart experi-
ence in Europe. J Heart Lung Transplant. 2007;26:219-29.
48. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al.
Advanced heart failure treated with a continuous flow left ventricular assist de-
vice. N Engl J Med. 2009;361:2241-51.
49. Westaby S, Siegenthaler M, Beyersdorf F, Massetti M, Pepper J, Khayat A, et al.
Destination therapy with a rotary blood pump and novel power delivery. Eur J
Cardiothorac Surg. 2010;37:350-6.
50. Westaby S, Jarvik R, Freeland A, Piggot D, Robson D, Saito S, et al. Postauric-
ular percutaneous power delivery for permanent mechanical circulatory support.
J Thorac Cardiovasc Surg. 2002;123:977-83.
51. Adamson RM, StahovichM, Chillcott S, Baradarian S, Chammas J, Jaski B, et al.
Clinical strategies and outcomes in advanced heart failure patient older than 70
years of age receiving the HeartMate II left ventricular assist device. J Am
Coll Cardiol. 2011;57:2487-95.
52. Westaby S, Frazier OH. Long term biventricular support with rotary blood
pumps. Prospects and pitfalls. Eur J Cardiothorac Surg. 2012;42:203-8.
53. Ibrahim M, Rao C, Athanasiou T, Yacoub MH, Terracciano CM. Mechanical un-
loading and cell therapy have a synergistic role in the recovery and regeneration
of the failing heart. Eur J Cardiothorac Surg. 2012;42:312-8.
54. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al.
INTERMACS profiles of advanced heart failure: the current picture. J Heart
Lung Transplant. 2009;28:535-41.
55. Eckman P, Rosenbaum A, Vongooru H, Basraon J, John R, Levy W. Survival of
INTERMACS profile 4-6 patients after left ventricular assist device implant is
improved compared to Seattle Heart Failure Model estimated survival. J Card
Fail. 2011;17:S38-9.
56. Westaby S. Lifetime circulatory support must not be limited to transplant centers.
Heart Fail Clin. 2007;3:369-76.
57. MacGowan GA, Parry G, Schueler S, Hasan A. The decline in heart transplanta-
tion in the UK. BMJ. 2011;342:d2483. http://dx.doi.org/10.1136/bmj.d2483.
58. Deng MC, Young JB, Stevenson LW, Oz MC, Rose EA, Hunt SA, et al. Destina-
tion mechanical circulatory support: proposal for clinical standards. J Heart Lung
Transplant. 2003;22:365-9.
59. Moazami N, Feldman D. Rethinking the terminology of mechanical circulatory
support. J Thorac Cardiovasc Surg. 2012;144:2-3.
60. Perin EC, Dohmann HE, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al.
Transendocardial autologous bone marrow cell transplantation for severe chronic
ischemic heart failure. Circulation. 2003;107:2294-302.ardiovascular Surgery c Volume 145, Number 1 31
